This research project will work with stroke survivors and their families. In year one, we will design a healthy living programme for stroke survivors and their families. The programme will provide information, education and support. It will help people to learn how to manage their own lifestyle risk factors.
The Stroke Association is a member of the Association of Medical Research Charities (AMRC). Published today, the AMRC have launched a new booklet outling highlighting how vital health information is to enable researchers to prevent, diagnose and treat disease and improve care.
CADASIL is one of the most common genetic causes of stroke and dementia. Currently, there is no treatment for CADASIL. In this study, human stem cells will be generated from a piece of skin donated by patients with CADASIL. From these stem cells, smooth muscle cells (SMCs) will be generated in a tissue culture dish in the lab.
This project aims to find out if peer support can avert some of the adverse psychological consequences of aphasia: the language and communication disorder that affects about 15% of those who have a stroke. Stroke survivors with long-term aphasia will be trained as peer befrienders.
Today, the Association of Medical Research Charities (AMRC) launched a new spotlight report highlighting the positive difference medical research charities are making for mental health patients across the UK.
This project aims to develop and test a repetitive functional task practice (RFTP) therapy programme. Research physiotherapists will develop the programme in conjunction with stroke unit staff and patients.
Early Supported Discharge (ESD) is the discharge of a stroke patient from hospital to their own home, co-ordinated by a team of therapists, nurses and a doctor. A number of ESD services have been set up across England. Do these services offer the same benefits to patients as those identified in clinical trials?
Thrombolysis, where drugs are injected into the blood to break up a blood clot, is one of the main treatments used to treat people who are having a stroke caused by a clot. Currently a drug called alteplase is used in thrombolysis. But the researchers think that another drug, called tenecteplase, may be more effective than alteplase. This study will investigate if this is the case.
Published online first in the journal Neurology, a new study suggests that people with AF who have an ICH due to their medication have similar outcomes whether they're on a NOAC or a vitamin K antagonist drug.
Thousands of lives a year could be changed thanks to a pilot research study by Imperial College which involves injecting a patient's stem cells into their brain.